5 patents
Utility
Ulinastatin Polypeptides
4 Jan 24
Provided are ulinastatin glycoforms, ulinastatin fusion polypeptides, and related compositions, mixtures, and methods of use, including methods of recombinantly producing ulinastatin polypeptides and treating diseases.
Rick PAULS, Todd VERDOORN, Karl Frank JOHNSON, Gregory Thomas BLECK
Filed: 21 Jun 23
Utility
Tissue KALLIKREIN-1 for Treating Chronic Kidney Disease
28 Dec 23
Provided are methods of using human tissue kallikrein-1 (KLK1) to treat chronic kidney disease (CKD) in patients having salt-sensitive hypertension and low KLK1 levels, including methods of identifying and treating optimal sub-populations of CKD patients based on selected genotypes and/or phenotypes.
Rick PAULS, David Wambeke, Nick Paulson
Filed: 5 Apr 23
Utility
Ulinastatin Polypeptides for Treating Diseases
4 Aug 22
Provided are methods and compositions comprising ulinastatin polypeptides for treating diseases associated with elevated neutrophil elastase (NE), including NE-associated lung and skin diseases.
Rick PAULS, David WAMBEKE, Sydney GILMAN
Filed: 27 Jan 22
Utility
Ulinastatin Polypeptides
9 Sep 21
Provided are ulinastatin glycoforms, ulinastatin fusion polypeptides, and related compositions, mixtures, and methods of use, including methods of recombinantly producing ulinastatin polypeptides and treating diseases.
Rick PAULS, Todd VERDOORN, Karl Frank JOHNSON, Gregory Thomas BLECK
Filed: 5 Mar 21
Utility
Dosage Forms of Tissue Kallikrein 1
13 May 21
Provided are dosage forms of one or more tissue kallikrein-1 (KLK1) polypeptides which have a total KLK1 polypeptide dosage of about 0.1 μg/kg to about 10.0 μg/kg, including subcutaneous and intravenous dosage forms.
Rick PAULS, Todd VERDOORN
Filed: 9 Mar 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first